CARDIOPATCH: Development of Advanced Therapies of Myocardial Infarction Treatment based on Regenerative Medicine and 3D Printing
Advancing Myocardial Infarction Therapeutic Treatment based on Regenerative Medicine and 3D Printing
The CARDIOPATCH project, coordinated by the Clínica Universidad de Navarra (CUN) and funded by the EU Interreg Sudoe Programme, aims to develop an innovative strategy to regenerate damaged tissue after myocardial infarction.
The consortium will develop a patch of collagen fibers functionalized with stem cells to optimize its therapeutic benefit and regenerative ability. In addition, the project will develop a 3D device to enable patch implementation through less invasive methods, and a 3D system to streamline its production and transport.
iBET and GeniBET Biopharmaceuticals (now part of Recipharm) will play a key role in the development of technologies and protocols for the production and characterization of different types of cells and cell-based products for application in regenerative medicine.
In addition to these therapeutic solutions, the CARDIOPATCH project will create a “Network of Excellence” in R&D in the biomedical sector in Southwest Europe, with the purpose of extending industry 4.0 technologies into the healthcare sector.
With a total budget of 1.4 million euros, the initiative includes partners from Spain, France and Portugal: CIMA Universidad de Navarra, through the Foundation for Applied Medical Research, Leartiker Technology Centre, la Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) – Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and iBET.
CARDIOPATCH project is co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF).